In the QUADRA trial, patients with recurrent platinum sensitive HRD ovarian cancer who had undergone at least 3 lines of prior therapy without prior exposure to PARP inhibitor demonstrated a significant response to niraparib (ORR 29%; 95% CI 16–44; p = 0.0003) [108]. Here, PARP1 is linked to ovarian cancer.